Sign In
Buy WXXWY
$9.88
+0.180 (+1.86%)
At Close: Jul 31, 2026
WuXi Biologics: Spotlight On Property Disposal And Operating Metrics (Rating Upgrade)
05:18pm, Tuesday, 21'st Jan 2025
My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin impr
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager
07:00pm, Monday, 06'th Jan 2025
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and i
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
07:00pm, Monday, 06'th Jan 2025
SHANGHAI and SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
07:50am, Monday, 06'th Jan 2025
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
04:30am, Thursday, 02'nd Jan 2025
Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI , Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK),
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
03:30am, Thursday, 12'th Dec 2024
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI , Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bi
WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations
07:19pm, Thursday, 05'th Dec 2024
Multiple successful 16,000L PPQ runs highlight that disposable manufacturing can achieve similar performance as traditional stainless reactors GMP Authorizations by HPRA demonstrate that new global si
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
11:00pm, Wednesday, 13'th Nov 2024
LEVERKUSEN, Germany , Nov. 13, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it wi
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
05:00am, Monday, 28'th Oct 2024
SHANGHAI , Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of W
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
08:00am, Wednesday, 16'th Oct 2024
HONG KONG , Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has rec
WuXi Biologics Included in Hang Seng ESG 50 Index
05:30am, Monday, 23'rd Sep 2024
HONG KONG , Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has be
By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity imp
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript
02:52pm, Thursday, 22'nd Aug 2024
WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ET Company Participants Lina Fan - Senior Vice President, Head of Investor Relations Chris Chen - Ch
WuXi Biologics Reports Solid 2024 Interim Results
11:46am, Wednesday, 21'st Aug 2024
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, inc
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
04:00am, Thursday, 08'th Aug 2024
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispeci
